A Multicenter, Open-Label, Two-Arm Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management
Phase of Trial: Phase IV
Latest Information Update: 21 Feb 2019
Price : $35 *
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors UCB Biopharma
- 31 Jan 2018 Status changed from active, no longer recruiting to completed.
- 21 Nov 2017 Planned End Date changed from 31 Dec 2017 to 1 Jan 2018.
- 21 Nov 2017 Planned primary completion date changed from 31 Dec 2017 to 1 Jan 2018.